Statement re. media comment
08 February 2021
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the article published online yesterday by the Financial Times.
The Company can confirm that it is continuing to modify its Alva-based facility to upscale significantly its lateral flow test production capacity. When contracts or supply agreements are signed to utilise this capacity the Company will announce this in line with AIM disclosure obligations.
|Omega Diagnostics Group PLC||Tel: 01259 763 030|
|Bill Rhodes, Interim Non-Executive Chairman|
Colin King, Chief Executive
|Kieron Harbinson, Group Finance Director|
|finnCap Ltd||Tel: 020 7220 0500|
|Geoff Nash/Edward Whiley (Corporate Finance)|
|Alice Lane (ECM)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Paul McManus||Mob: 07980 541 893|
|Lianne Cawthorne||Mob: 07584 391 303|